Comparative therapeutic effects of metformin and vitamin E in a model of nonalcoholic steatohepatitis in the young rat. by MATTACE RASO, Giuseppina et al.
European Journal of Pharmacology 604 (2009) 125–131
Contents lists available at ScienceDirect
European Journal of Pharmacology
j ourna l homepage: www.e lsev ie r.com/ locate /e jpharPulmonary, Gastrointestinal and Urogenital Pharmacology
Comparative therapeutic effects of metformin and vitamin E in a model of
non-alcoholic steatohepatitis in the young rat
Giuseppina Mattace Raso a, Emanuela Esposito b, Anna Iacono a, Maria Pacilio a, Salvatore Cuzzocrea b,c,
Roberto Berni Canani d, Antonio Calignano a, Rosaria Meli a,⁎
a Department of Experimental Pharmacology, University of Naples “Federico II”, Naples, Italy
b IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
c Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Messina, Italy
d Department of Pediatrics, University of Naples “Federico II” Naples, Italy⁎ Corresponding author. Department of Experimental P
49-80131 Naples, Italy. Tel.: +39 081 678413; fax: +39 081
E-mail address: meli@unina.it (R. Meli).
0014-2999/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.ejphar.2008.12.013a b s t r a c ta r t i c l e i n f oArticle history: Only in the last few years h
Received 9 July 2008
Received in revised form 18 November 2008
Accepted 2 December 2008
Available online 14 December 2008
Keywords:
Steatohepatitis
High fat diet
Metformin
Vitamin E
Pro-inﬂammatory mediator
Peroxisome proliferator-activated receptoras non-alcoholic steatohepatitis been recognized as an important and relatively
common liver disease. To date, the therapeutic options are limited, vitamin E and metformin have been
proposed for the treatment of this condition, although their mechanisms are not completely clariﬁed as yet.
The aim of this study was to investigate the anti-inﬂammatory and anti-oxidative mechanisms of these drugs
in an experimental model of non-alcoholic steatohepatitis in the young rat. Male rats, just after weaning,
were divided into four groups: a control group that received a standard diet; a high fat diet group; two high
fat diet fed groups treated with vitamin E or metformin, respectively. After 4 weeks, we evaluated in the liver
the modiﬁcation of lipid peroxidation, assessed by malondialdehyde, TNF-α levels, S-nitrosylated protein,
inducible nitric oxide sinthase (iNOS), and peroxisome proliferators-activated receptors (PPAR) expression
and metalloproteinase activity. High fat diet increased malondialdehyde, nitrotyrosilated proteins, and TNF-α
tissue content. Moreover, a decrease of PPAR-α and an increase of PPAR-γ expression were observed. An
increase of metalloproteinase activity was also shown. Among drug treatments, metformin reduced body
weight gain and fat mass, metalloproteinase activity, and TNF-α tissue content, while it restored PPAR-α
expression and downregulated PPAR-γ expression. Vitamin E reduced the oxidative damage, protein
nitrotyrosilation, and tissue TNF-α levels. Moreover a decrease of PPAR-γ expression was also shown. These
ﬁndings conﬁrm the efﬁcacy of both drugs as therapeutic tools in preventing the early onset of liver damage
and non-alcoholic fatty liver disease progression.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe hallmark of non-alcoholic steatohepatitis is the accumulation
of large-droplet fat in hepatocytes, including fat alone as well as fat
with non-speciﬁc inﬂammation. Although several predisposing
factors, such as obesity, insulin resistance and type 2 diabetes, are
related to the pathogenesis of non-alcoholic steatohepatitis, the exact
mechanism of its progression to ﬁbrosis and chronic liver disease is
still unclear (Farrell and Larter, 2006). Simple steatosis and non-
alcoholic steatohepatitis are similar in terms of excessive accumula-
tion of fatty acids in the hepatocytes, that protect themselves by
binding, transforming, catabolizing, and exporting excess of free fatty
acids. The β-mitochondrial oxidation of these fatty acids is a source ofharmacology, via D. Montesano,
678403.
l rights reserved.free radicals and produces hydrogen peroxide and reactive oxygen
species. Lipid peroxidation, together with cytokines, and other pro-
inﬂammatory compounds are believed to play a critical role in the
transition from steatosis to non-alcoholic steatohepatitis (Farrell and
Larter, 2006; McCullough, 2006). The ligand-activated transcription
factors belonging to the peroxisome proliferators-activated receptor
(PPAR) family are involved in the regulation of energy homeostasis
and inﬂammation. In particular, PPAR-α is prominently expressed in
the liver, where its activation results in increased uptake and
oxidation of free fatty acids (Reddy, 2001). Increased expression of
PPARγ has been reported in high-fat diet-induced liver steatosis
(Inoue et al., 2005). Overexpression of PPARγ1 in liver of PPARα null
mice induced the expression of lipogenesis-related genes, leading to
hepatic steatosis (Yu et al., 2003). PPARγ2 has also been reported to
induce lipid accumulation in hepatocytes (Schadinger et al., 2005).
Weight reduction through a healthy diet and a regular medium-
intensity exercise is the mainstay of the current treatment, especially
in children.
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different steps in the pathogenesis of development of hepatic steatosis
or progression to steatohepatitis in children (Kerkar, 2004; Roberts
and Yap, 2006). Vitamin E (alpha-tocopherol) is a potent antioxidant
particularly effective against membrane lipid peroxidation, therefore
it is considered a cytoprotective agent. Besides, it has already been
claimed as a possible therapeutic approach of non-alcoholic steato-
hepatitis in pediatric patients, in that it shows an improvement of
serum aminotransferases (Lavine, 2000; Vajro et al., 2004).
Metformin is an insulin-sensitizing agent reported to reverse
hepathomegaly, steatosis and liver tests abnormalities in a model of
fatty liver (Lin et al., 2000). Clinical data reported a controversial
metformin effect on liver damagemarkers (Marchesini et al., 2001; Nair
et al., 2004; Bugianesi et al., 2005; Schwimmer et al., 2005). A recent
meta-analysis about drugs improving insulin resistance in non-alcoholic
steatohepatitis suggests that further clinical studies are needed to either
support or refute the use of these drugs, which are however rated as
having a favourable role (Angelico et al., 2007).
The aim of the present study was to comparatively evaluate the
therapeutic effect of vitamin E and metformin in an experimental
model of non-alcoholic steatohepatitis induced in the young rat.
For this purpose, young male rats, just after weaning, were allowed
free access to high-fat diet, to induce the typical pathological features of
steatosis (Lieber et al., 2004a,b). This animal model of steatosis,
differently from a genetically modiﬁed animal (e.g. ob/ob mouse),
might better mirror what happens in the human non-alcoholic
steatohepatitis due to fatty diets.
In particular, 4 weeks after drug treatments, we investigated the
modiﬁcations of liver lipid peroxidation, evaluated as malonyldialde-
hyde and tissue TNF-α content, hepatic protein nitrotyrosilation,
inducible nitric oxide (iNOS), and PPAR-α and PPAR-γ expression.
Moreover, we evaluated the activity of metalloproteinases, in particular
metalloproteinase-2 and metalloproteinase-9.
2. Materials and methods
2.1. Drugs and reagents
High-fat liquid diet was purchased from Research Diets Inc. (New
Brunswick, NJ, USA). Standard diet (Global diet 2018) was purchased
from Harlan Italy (San Pietro al Natisone, Udine, Italy). Vitamin E and
metformin (1,1-dimethylbiguanide hydrochloride) were purchased
from Sigma Chemicals (Milan, Italy).
2.2. Animals and treatments
Youngmale Sprague-Dawley rats (average body weight 115.3±3.1 g)
were purchased from Charles River Laboratories (Wilmington, MA, USA)
and randomly divided into four groups (n=6 animals for each group) as
following: 1) a control group receiving the standarddiet, 2) a high fatdiet
fed group; 3) high fat diet fed animals treated by gavage with vitamin E
(30 UI/kg/daily), and 4) high fat diet fed animals treated by gavage with
metformin (250 mg/kg/daily). Rats from the high fat diet and control
groups were gavaged water as vehicle. After weaning, the animals were
allowed free access to a standard diet containing 15% of energy derived
from fat, 22% from protein, and 63% from carbohydrate or to a high fat
diet that contained 71% of energy derived from fat, 11% from
carbohydrates, and 18% from protein. This diet rich in unsaturated fat
and low in carbohydratesdeveloped thepathologic changes, key features
of non-alcoholic steatohepatitis, already at 3 weeks, as previously
reported (Lieber et al., 2004a,b). The pharmacological treatment started
togetherwith the high fat diet and continued for 4weeks. All procedures
involving the animals were carried out in accordance with the
Institutional Guidelines and complied with the Italian D.L. no.116 of
January 27,1992and associated guidelines in the EuropeanCommunities
Council Directive of November 24, 1986 (86/609/ECC).2.3. Animal body weight, fat mass and tissue collection
All rats were weighed after weaning and before sacriﬁce, in order to
calculate body weight modiﬁcations as obtained during the experi-
mental period, elicitedbydifferentdiets and treatments. Throughout the
treatment period food intake was monitored once a week. Bioelectrical
impedance analysis was applied to assess body composition at 4 weeks
using aBIA 101 analyzer,modiﬁed for rat (Akern, Florence, Italy). Fat-free
masswas calculated using the bioelectrical impedance analysis (50 kHz)
prediction equation of Ilagan et al. (1993), and fat mass content was
determined as the difference between body weight and fat-free mass.
After 4weeks treatment, all animalswere anesthetized byenﬂurane and
sacriﬁced by cervical dislocation. The livers were excised weighed and
immediately frozen in liquid nitrogen and used for later experimental
procedures. Blood was collected by cardiac puncture and centrifuged at
1500 ×g at 4 °C for 15 min and sera were stored at −70 °C for later
measurements of aspartate amino transferase (AST), and alanine amino
transferase (ALT) by standard automated procedures. In order to
evaluate the effect of pharmacological treatment on steatosis, hepatic
triglyceride content was alsomeasured by using commercially available
kit (Wako Pure Chemical Industries, Japan).
2.4. Liver Malonyldialdehyde and TNF-α level in livers
Malonyldialdehyde levels in the livers were determined as an
indicator of lipid peroxidation. Tissues were homogenized in 1.15% KCl
solution. An aliquot (200 µl) of the homogenate was added to a reaction
mixture containing 200 µl of 8.1% SDS,1.5ml of 20% acetic acid (pH 3.5),
1.5 ml of 0.8% thiobarbituric acid, and 600 µl of distilled water. Samples
were then boiled for 1 h at 95 °C and centrifuged at 3000 ×g for 10 min.
The supernatant absorbance was measured by spectrophotometry, and
malonyldialdehyde valueswere calculated by comparisonwith OD550 of
standard solutions of malonyldialdehyde bis (dymethyl acetal) 1,1,3,3-
tetramethoxypropan 99% (Sigma, Milan, Italy).
Portions of liver tissues were homogenized and tissue TNF-α levels
were evaluated, using a colorimetric, commercial kit (Calbiochem-
Novabiochem Corporation, USA) according to themanufacturer instruc-
tions. All TNF-α determinations were performed in duplicate serial
dilutions.
2.5. Nitrotyrosine detection, iNOS, PPAR-α and PPAR-γ expression by
Western blotting
Liver tissue (0.1 g) was disrupted by homogenization on ice in a lysis
buffer. Protein lysates were subjected to SDS-PAGE (8% polyacrylamide).
The blot was performed by transferring proteins from a slab gel to a
nitrocellulose membrane (Protran nitrocellulose transfer membrane;
Whatman Schleicher and Schuell, Dassel, Germany) and probed with
speciﬁc antibodies against PPAR-α (Santa CruzBiotechnology, Inc., Santa
Cruz, CA; 1:500), PPAR-γ (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
1:100), or anti-3-nitrotyrosine antibody (Upstate Biotechnology, Lake
Placid, NY; 1:5000). The secondary antibody (antirabbit IgG peroxidase
conjugate) was incubated for 1 h at room temperature. Western blot for
β-actinprotein (Sigma; 1:10 000)wasperformed toensure equal sample
loading. The protein bands of iNOS (~130 kDa), PPAR-α (~55 kDa), and
PPAR-γ (~55 kDa) on x-Omat ﬁlm (Eastman Kodak, Rochester, NY) were
scanned and densitometrically analyzed with a model GS-700 imaging
densitometer (Bio-Rad Laboratories, Hercules, CA).
2.6. MMPs activity
Gelatin-zymography was performed to determine the level of the
active and pro-enzyme forms of MMPs, as previously described (Okada
et al., 2001). Brieﬂy, aliquots of liver standardised homogenates were
subjected to electrophoresis in (2 mg/ml) gelatin-containing polyacry-
lamide gels in the presence of SDS under non-reducing conditions. After
Table 1
Modiﬁcation of liver weight and transaminases in control (CON) or high fat diet fed rats
(HFD) treated with vitamin E (HFD+VIT E) or metformin (HFD+MET) for 4 weeks
CON HFD VIT E MET
Liver weight (g/100 g) 3.82±0.07 4.42±0.08a 4.12±0.18 4.11±0.18
Liver triglyceride (mg/g) 100.3±4.2 274.3±14.5b 203.3±23.0c 178.0±15.3d
ALT (U/l) 45.25±2.02 60.25±2.29a 45.00±1.78c 56.00±4.32
AST (U/l) 161.80±4.53 236.50±16.54a 204.30±13.94 154.50±18.67c
Values are means±S.E.M. of 4 rats.
a Pb0.05 vs CON.
b Pb0.001 vs CON.
c Pb0.05 vs HFD.
d Pb0.01 vs HFD.
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overnight in 0.1 M Tris–HCl gelatinase-activation buffer (pH 7.4)
containing 10mMCaCl2 and subsequently stained with 0.5% Coomassie
Blue. After intensive destaining, proteolysis areas appeared as clear
bands against a blue background.
MMPs were identiﬁed by their molecular weight compared with
standards. 1,10-Phenanthroline, a general inhibitor of metalloproteinases,
completely blocks both the inactive and active forms, thus conﬁrming the
speciﬁcity of these molecules (data not shown). Tomeasure the activities
of the detected enzymes, zymograms were read using a ScanJet 3c
scanner (Hewlett-Packard, Boise, ID). The intensities of the separate bands
wereanalyzedusingSigmaGelmeasurement software (Jandel, SanRafael,
CA). Quantitative evaluations of both surface and intensity of lysis bands,
on the basis of grey levels, were compared relative to non-treated control
wells and expressed as ‘relative expression’ of gelatinolytic activity.
2.7. Statistical analysis
All data were presented as mean±S.E.M. All analysis were conducted
usingGraph-PadPrism(Graph-Padsoftware Inc., SanDiego, CA). StatisticalFig.1. Bodyweight gain (A) and fat mass (B) in rats from control diet (CON), high-fat diet
(HFD) or high fat diet-fed groups treated with vitamin E (HFD+VIT E) or metformin
(HFD+MET) for 4 weeks. Body weight gainwas expressed in g/28 days. Values are given
as means±S.E.M. of 6 rats.⁎Pb0.05, ⁎⁎Pb0.01, and ⁎⁎⁎Pb0.001 vs CON; #Pb0.05,
###Pb0.001 vs HFD.analysiswas performedbyANOVA test formultiple comparisons followed
by Bonferroni's test. Statistical signiﬁcance was set at Pb0.05.
3. Results
3.1. Effect of drugs treatment on body and liver parameters
In rats receiving the high fat diet a signiﬁcant increase in liverweight,
hepatic triglyceride content and ASTand ALT serum levelswas observed
as comparedwith rats receiving control diet (Table 1). Despite vitamin EFig. 2.Malonyldialdehyde (MDA) content (A), protein nitrotyrosilation levels (B), and iNOS
expression (C) in liver from control diet (CON), high-fat diet (HFD) or high-fat diet -fed
groups treated with vitamin E (HFD+VIT E) or metformin (HFD+MET) for 4 weeks.
Malonyldialdehyde values, expressed as µM/mgprotein, aremean±S.E.M. of 5 animals. The
data in panel C represent relative density normalized to β-actin. ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 vs
CON; #Pb0.05, ###Pb0.001 vs HFD.
Fig. 4. Representative Western blot of PPAR-α (A) and PPAR-γ (B) expression in tissue
lysates of liver from control diet (CON), high-fat diet (HFD) or high-fat diet-fed groups
treated with vitamin E (HFD+VIT E), or metformin (HFD+MET) for 4 weeks is shown.
PPAR-α and PPAR-γ modulation was revealed by densitometric analysis of all protein
bands. The data represent relative density normalized to β-actin. Values are given as
means±S.E.M. of 6 rats. ⁎Pb0.05 vs CON; #Pb0.05 vs HFD.
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were able to decrease ALT or AST (Pb0.05), respectively, which were
altered in the high fat diet fed group. Both drugs signiﬁcantly reduced
liver triglyceride content and therefore steatosis extent.
Moreover, in rats receiving high fat diet a signiﬁcant increase in
body weight gain and fat mass was observed with respect to the
control diet group (Fig. 1A). The treatment with metformin signiﬁ-
cantly inhibited body weight gain and fat mass induced by high fat
diet. Vitamin E treatment, while not signiﬁcantly modifying body
weight gain, conversely presented a signiﬁcant decrease in fat mass
content compared to that of high fat diet fed rats (Fig. 1B). No variation
in food intake was shown between the high fat diet fed group and
metformin or vitamin E treated high fat diet fed animals (192.0±7.20
vs 183.8±3.57 and 189.6±9.74 ml/4 weeks, respectively).
3.2. Effect of drugs on increased lipid peroxidation and S-nitrosylation
induced by high fat diet in liver
Malonyldialdehyde and other malonyldialdehyde-like aldehydes
and ketones are generated by phospholipids peroxidation. In
particular malonyldialdehyde is the major product reacting with
thiobarbituric acid. High fat diet induced a marked increase in the
amount of malonyldialdehyde (Fig. 2A; Pb0.001 vs control), and
vitamin E treatment signiﬁcantly reversed this effect (Pb0.001 vs high
fat diet fed group). No signiﬁcant decreasing trend of lipid peroxida-
tion was evident (t=2.576) in metformin treated animals.
We have also determined the levels of nitrotyrosines (downstream
reaction products of peroxynitrite) of hepatic proteins and iNOS
expression by Western blot analysis. The increase of these parameters
may result in inﬂammation and liver damage. Nitrosylation of hepatic
protein of high fatdiet fed animals (Fig. 2B)wascoupled to aparallel iNOS
induction (Fig. 2C) compared with control rats and all pharmacological
treatments reversed signiﬁcantly these modiﬁcations to control levels.
3.3. TNF-α modulation by pharmacological treatments in liver from high
fat diet fed rats
As reported in Fig. 3, a signiﬁcant increase in tissue TNF-αwas found
in liver from high fat diet fed animals (Pb0.01). This effect was
signiﬁcantly reverted by vitamin E or metformin (Pb0.001 and Pb0.05,
respectively), contributing to their anti-inﬂammatory activity.
3.4. Effect of pharmacological treatments on PPAR-α and PPAR-γ
expression
High fat diet induced a signiﬁcant decrease of PPAR-α in liver
lysates (Pb0.05; Fig. 4A) and only metformin treatment signiﬁcantly
prevented the high fat diet-induced PPAR-α degradation (Pb0.05). OnFig. 3. Liver TNF-α levels, expressed as pg/100mgof tissue,were obtained fromcontrol diet
(CON), high-fat diet (HFD) or high-fat diet-fed groups treated with vitamin E (HFD+VIT E),
ormetformin (HFD+MET) for 4weeks. Values are given asmeans±S.E.M. of 6 rats. *Pb0.05,
and **Pb0.01 vs CON; #Pb0.05, ##Pb0.01, and ###Pb0.001 vs HFD.the contrary, PPAR-γ expressionwas upregulated in liver from high fat
diet fed animals, and both treatments prevented its increase (Fig. 4B).
3.5. Evaluation of hepatic proMMP-2 and proMMP-9 activity
MMPs plays an important role in the pathogenesis and evolution of
inﬂammatory diseases.We determined the activity of gelatinaseA and B
(MMP-2 and pro MMP-9, respectively) in livers from all groups, since
they are principally involved in liver damage. As reported in Fig. 5, both
pro-MMP-2 and pro MMP-9 were signiﬁcantly up-regulated in liver
fromHFDanimals (Fig. 5). Even if a trend to decrease for both proMMP-2
and proMMP-9 was revealed, vitamin E reduced signiﬁcantly the active
form of MMP-2. Conversely metformin treatment signiﬁcantly reduced
all MMPs activity. The lack of active MMP-9 in the zymogram could be
due to its high level of instability and to the removal of active enzyme
during thewashingof specimens, as reportedabove (Deleve et al., 2003).
4. Discussion
Non-alcoholic steatohepatitis is an increasingly recognized condition
that may eventually progress to an end stage liver disease. A net
retention of lipids within hepatocytes is a prerequisite for the
development of the disease. Increased intrahepatic levels of fatty acids
provide a source of oxidative stress which may in large part be
Fig. 5. Active and proMMP-2 and proMMP-9 activity in liver lysates from control diet (CON), high-fat diet (HFD) or high-fat diet-fed groups treated with metformin (HFD+MET) or
vitamin E(HFD+VIT E) for 4 weeks was shown by gelatin-zymography. Densitometric analysis of proMMP-2 (A), proMMP-9 (B) and active MMP-2 (C) bands was also reported. Values
are given as means±S.E.M. of 6 rats. ⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001 vs CON; #Pb0.05, and ##Pb0.01 vs HFD.
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cirrhosis.
Pathophysiology of this condition still has not been so far clariﬁed.
The presumed factors initiating the progression of non-alcoholic
steatohepatitis are insulin resistance (Bugianesi et al., 2005; Larter and
Farrell, 2006), an increased oxidative status with subsequent lipid
peroxidation, pro-inﬂammatory cytokines (principally TNF-α), and
hormones derived from adipose tissue (adipocytokines) (Albano et al.,
2005; Duvnjak et al., 2007; Kojima et al., 2007).
As already reported by Lieber et al. (2004a,b), a 3 weeks feeding with
high fat diet induced pronounced hepatic steatosis and abundant
mononuclear inﬂammatory cells evidenced by histopathological analysis.
In our experimental conditions, we prolonged to 4weeks the high fat diet
assumption and we reported a crucial and signiﬁcant alteration of liver
parameters (liverweight, transaminases, trygliceride content), induced by
high fat diet. Moreover, we demonstrated that in young rat this diet
induced a signiﬁcant increase in the malonyldialdehyde content in the
liver.Malonyldialdehydeandother substances, suchas4-hydroxynonenal,
8-isoprostane, and 3-nitrotyrosine are produced by lipid peroxidation and
the level in the plasma of several oxidative stress markers was found to
have increased in non-alcoholic steatohepatitis patients (Loguercio et al.,
2001; Sumida et al., 2003). In our experimental conditions, the high
oxidative damage induced by 4-week high fat diet was conﬁrmed by theincrease of liver protein S-nitrosylation, that was accompanied with an
increase of iNOS.
Moreover, we found a signiﬁcant decrease in PPAR-α expression in
liver from the high fat diet fed group, most likely related to the
progression of steatosis. Conversely, an upregulation of PPAR-γ was
shown. As known, PPAR-α activation reduces or even reverses
steatohepatitis induced by a methionine- and choline-deﬁcient diets
and a loss of expression in PPAR-α gene in mice results in hepatic
steatosis under conditions of an increased fatty acid metabolism in the
liver, such as in fasting or a high fat diet (Kallwitz et al., 2008). The anti-
inﬂammatory role of PPAR-α in the development of steatohepatitis is
further supported by the evidence that animals lacking PPAR-α
developed steatohepatitis accompanied by an increased number in
inﬁltrated lymphocytes andmacrophages (KashireddyandRao, 2004). A
role for hepatic PPAR-γ in liver trygliceride accumulation has been also
suggested, indeed PPAR-γ deﬁcient mice are protected against devel-
opment of steatosis. Conversely, even if this receptor isoform is able to
protect other tissues from triglyceride accumulation and insulin
resistance, it contributes to hepatic steatosis, regulating triglyceride
homeostasis (Gavrilova et al., 2003). Moreover, a high fat diet increased
PPAR-γ expression together with cAMP-response element-binding
protein, an upstream molecule of PPAR-γ signalling, in the nuclei of
hepatocytes in mice (Inoue et al., 2005).
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of prometalloproteinase-2 and prometalloproteinase-9 in the high fat
diet fed group was signiﬁcantly higher than that of animals fed with
control diet, thus showing the involvement of prometalloproteinases
in the evolution of the liver inﬂammatory process induced by high fat
diet. These prometalloproteinases degrade the basement membrane
and extracellular matrix, facilitate leukocyte migration and the release
of TNF-α from its membrane-bound form (McGeehan et al., 1994).
In this model we used two therapeutic tools, i.e., metformin, as
insulin sensitizers and vitamin E, as cytoprotective agent.
Metformin was reported to reverse hepathomegaly, steatosis and
liver tests abnormalities in amodel of fatty liver (Lin et al., 2000). Several
clinical studies conﬁrm the improvement in liver tests, insulin
sensitivity, and loss of body weight (Marchesini et al., 2001; Angulo
and Lindor, 2002; Schwimmer et al., 2005) induced by metformin
treatment, even if someother results showednoeffect (Nair et al., 2004).
Although an amelioration of aminotransferase level and liver histology
was evidenced, on the other hand, no statistically signiﬁcant change in
the severity of liver inﬂammation or ﬁbrosis after metformin treatment
was reported (Uygun et al., 2004).
In our experimental conditions, as expected, this drug reduced
body weight gain and fat mass in comparison to high fat diet fed
animals. It did not signiﬁcantly reduce liver weight, but ameliorates
transaminase proﬁle and reduced signiﬁcantly liver trygliceride
content. Although having a slight effect on lipid peroxidation
(malonyldialdehyde content) metformin was found markedly reduce
nitrotyrosylation of hepatic proteins and to strongly inhibit the
induction of iNOS. This anti-inﬂammatory effect was conﬁrmed by
inhibition of TNF-α content in liver tissue and of MMPs activity.
Metformin effect on lipid metabolism was also evidenced by the
normalization of liver PPAR-α and PPAR-γ expression, resulting in an
inhibition of steatosis progression.
On the other hand, vitamin E treatment did not signiﬁcantlymodify
body weight gain and liver weight, but slightly reduced fat mass and
ameliorated transaminase proﬁle. It strongly reduced hepatic trygli-
ceride content, the oxidative damage, protein nitrotyrosilation, and
iNOS expression. The cytoprotective effect of vitamin E was conﬁrmed
by inhibition of TNF-α content in liver tissue, while no modiﬁcation of
MMPs activity was evidenced. Differently from metformin, vitamin E
did not modify PPAR-α expression, showing a lean effect on lipid
metabolism; conversely it normalizes liver PPAR-γ expression, linked
to the partial reduction of liver inﬂammatory damage.
Together with metformin, the second generation thioglitazones are
also able to improve insulin sensitivity and considered a candidate for
non-alcoholic steatohepatitis treatment, as they stimulate the storage of
free fatty acids in subcutaneous adipocytes as opposed to liver and
omental fat. They show anti-inﬂammatory properties, downregulating
NF-kB activity and increasing adiponectin levels (Mohanty et al., 2004;
Lutchman et al., 2006). Anyway, their use in paediatric patients has to be
taken with care, since even if safer than ﬁrst generation drugs, they are
contraindicated in the presence of active liver disease or of elevated ALT
level. Moreover, the treatment with these agents may need to be life-
long as evidenced by recourse to steatosis after drug cessation
(Lutchman et al., 2007). Larger multi-year clinical trials are necessary
to determine their efﬁcacy and safety, since cardiovascular risks and
weight gain are associated to their use (Nathan, 2007; Promrat et al.,
2004). Due to all these limits, the use of these thioglitazones in children
is not advisable.
To avoid liver disease progression, prevention of liver damage is
particularly urgent ever since the early age. Therefore, to date among the
major potential therapeutic options, insulin sensitizers, such as
metformin, and antioxidant vitamin E (Bugianesi et al., 2006; Mishra
and Younossi, 2007) are surely efﬁcacious and well-tolerated, but their
long-term clinical efﬁcacy either alone or in combination has not yet
been conﬁrmed. Although experimental and clinical studies suggest for
these drugs a favourable role in improving non-alcoholic fatty liverdisease, further investigations and large randomized trials will be
needed.
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